Evidence map›Paper›PMID 41166056›Full record

SynthesisInternational journal of clinical pharmacy2025

Economics, efficacy and safety of five traditional Chinese medicine injections plus chemotherapy as adjuvant therapy for non-small cell lung cancer: A network meta-analysis.

Kai Xu, Hongtao Li, Yulu Zhu, Zhuying Jing, Lihong Gao, Yuyang Sun, Baolong Ding, Hongting Yao, Hui Wang, Xin Li

Abstract readSystematic ReviewNetwork Meta-Analysis
PubMed Publisher
In one paragraph

Synthesis in International journal of clinical pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kai XuDepartment of Pharmacy, The Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu, China.
Hongtao LiDepartment of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical University, No.101 Longmian Avenue, Jiangning District, Nanjing, 211166, Jiangsu, People's Republic of China.
Yulu ZhuDepartment of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical University, No.101 Longmian Avenue, Jiangning District, Nanjing, 211166, Jiangsu, People's Republic of China.
Zhuying JingDepartment of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical University, No.101 Longmian Avenue, Jiangning District, Nanjing, 211166, Jiangsu, People's Republic of China.
Lihong GaoDepartment of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical University, No.101 Longmian Avenue, Jiangning District, Nanjing, 211166, Jiangsu, People's Republic of China.
Yuyang SunDepartment of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical University, No.101 Longmian Avenue, Jiangning District, Nanjing, 211166, Jiangsu, People's Republic of China.
Baolong DingDepartment of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical University, No.101 Longmian Avenue, Jiangning District, Nanjing, 211166, Jiangsu, People's Republic of China.
Hongting YaoDepartment of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical University, No.101 Longmian Avenue, Jiangning District, Nanjing, 211166, Jiangsu, People's Republic of China.
Hui WangDepartment of Radiology, Nanjing City QiXia District Qixia Community Healthcare Center, Nanjing, Jiangsu, China.
Xin LiDepartment of Pharmacy, The Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu, China. xinli@njmu.edu.cn.ORCID http://orcid.org/0000-0003-3951-8061

Funding

National Natural Science Foundation of China 72074123
6 · The paper itself

Abstract

introductionLung cancer remains a leading cause of cancer-related morbidity and mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for > 85% of cases. Traditional Chinese Medicine (TCM) has played an integral role in NSCLC management, particularly in combination with chemotherapy. Although the safety and efficacy of TCM injections have been widely studied, comprehensive pharmacoeconomic evaluations remain limited.

aimThis review aimed to evaluate the safety, efficacy, and cost-effectiveness of five TCM injections, Marsdenia tenacissima, Aidi, Kanglaite, Kangai, and Shenqi Fuzheng, in combination with chemotherapy for the treatment of advanced NSCLC.

methodA systematic literature review identified 165 randomized controlled trials (RCTs) published between 2000 and 2024. A Bayesian network meta-analysis (NMA) was performed to compare the objective response rates (ORR) and adverse events (AEs) among the five TCM injections plus chemotherapy versus chemotherapy alone. A decision tree model with a 6-month time horizon was constructed from the healthcare system perspective, incorporating direct medical costs, including drug administration, monitoring, and AE management. The incremental cost-effectiveness ratios (ICERs) were calculated based on incremental ORR improvements. One-way and probabilistic sensitivity analyses were performed to test the robustness of the model.

resultsAll five TCM injections combined with chemotherapy demonstrated superior ORR compared with chemotherapy alone. Kanglaite injection showed the highest ORR improvement (12.5%) and lowest incidence of leukopenia and hepatic dysfunction. However, Kangai injection exhibited the lowest ICER of $19.56 per 1% ORR gain, indicating the highest cost-effectiveness. The ICERs for the remaining regimens were $43.38 (Marsdenia tenacissima), $29.68 (Aidi), $56.94 (Kanglaite), and $28.08 (Shenqi Fuzheng) per 1% ORR. Sensitivity analyses confirmed the robustness of these findings, with ORR and injection costs identified as the key drivers.

conclusionAmong the five TCM injections evaluated, Kangai injection combined with chemotherapy has emerged as the most cost-effective regimen for advanced NSCLC. These findings support the integration of TCM into evidence-based cancer care, and highlight the need for further pharmacoeconomic research, particularly in real-world clinical settings.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungDrugs, Chinese HerbalLung NeoplasmsMedicine, Chinese TraditionalChemotherapy, AdjuvantCost-Benefit AnalysisHumansInjectionsRandomized Controlled Trials as TopicTreatment Outcomeaidi herbal drugDrugs, Chinese Herbalkang-lai-teshenqi fuzhengCost-effectiveness analysisNetwork meta-analysisNon-small cell lung cancerTraditional Chinese medicine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.